Journal of Scientific and Technical Research (Sharda University, Noida)

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Review:Chitosan Nanoparticles for Effective and Safe Drug Delivery:Potential Big Deal in Intellectual Property Business


Affiliations
1 Nano Technology Research Laboratory, Department of Electronics, Wayamba University of Sri Lanka, Kuliyapitiya, Sri Lanka
     

   Subscribe/Renew Journal


According to the world drug report 2016 of United Nations Office on Drug and Crime, over 29 million people who use drugs are estimated to suffer from drug use disorders. It is estimated that 1 in 20 adults, or a quarter of a billion people between the ages of 15 and 64 years, used at least one drug in 2014. The estimated 207, 400 drug-related deaths in 2014 is corresponding to 43.5 deaths per million people aged 15-64. The number of drug-related deaths worldwide has also remained stable, although unacceptable and preventable.

The use of conventional antimicrobial agents against infections is always associated with problems such as the development of multiple drug resistance and adverse side effects. In addition, the inefficient traditional drug delivery system results in inadequate therapeutic index, low bio-availability of drugs, inefficient delivery of the drugs, causing systemic side effects, problems of poor uptake and destruction of drugs (when orally administered).

One of the most dynamic research areas in the field of nanotechnology is nano-medicine and target drug delivery is one of the highly specific medical interventions for prevention, diagnosis and treatment of diseases. Problems associated with conventional drug administration methods may potentially be overcome by these novel drug delivery methods. Researchers have been able to develop targeted and sustained drug delivery platforms harnessing unique physico-chemical properties of nano-particles. Advances in research on bio-compatible polymeric nano-particles have enabled more efficient and safer delivery of drugs with improved pharmacokinetics and pharmacodynamics with reduced side effects. Total market size of nanotechnology in drug delivery in 2021 is forecasted to be US$136 billion. Trends also suggest that the number of nanotechnology products and workers worldwide will double every 3 years, achieving a US$3 trillion market with six million workers by 2020. Chitosan nanoparticles seem to be the most promising comnanoparticle that can be used for developing multipurpose drug carrier platforms due to its biocompatibility, mucoadhesivity, non-toxicity and biodegradability.

Despite of potential benefits of nanoparticles in target drug delivery, there are certain engineered nanomaterials which can lead to unforeseen environmental, health and safety risks. Therefore, adequate attention is needed from the beginning in order to ensure sustainable nanotechnology. This review article is focused on frontier research, toxicity evidence and patent filing trends in applications of chitosan nanoparticles with an emphasis on target drug delivery.


Keywords

Biocompatible, Chitosan Nanoparticles, Hazards and Risks, Nanomedicine, Nanotechnology, Patents, Pharmacodynamics, Pharmacokinetics, Targeted Drug Delivery.
User
Subscription Login to verify subscription
Notifications
Font Size

  • R. R. Bhagwat, and I. S. Vaidhya, “Novel Drug Delivery System: An Overview,” International Journal of Pharmaceautical Sciences and Research, vol. 4, no. 3, pp. 970-982, 2013.

  • Y. Diebold, and M. Calonge, “Applications of nanoparticles in ophthalmology,” Progress in Retinal and Eye Research, vol. 29, no. 6, pp. 596-609, 2010.

  • T. Cerna, T. Eckschlager, and M. Stiborova, “Targeted nanoparticles - a promising opportunity in cancer therapy - Review,” Journal of Metallomics and Nanotechnologies, vol. 2, no. 4, pp. 6-11, 2015.

  • W. H. D. Jong, and P. J. A. Borm, “Drug delivery and nanoparticles: Applications and hazards,” International Journal of Nanomedicine, vol. 3, no. 2, pp. 133-149, June 2008.

  • W. Gao, J. C. K. Lai, and S. W. Leung, “Functional enhancement of chitosan and nanoparticles in cell culture, tissue engineering, and pharmaceutical applications,” Frontiers in Physiology, vol. 3, article no. 321, pp. 1-11, August 2012.

  • C. Garber, “The potential and the pitfalls of nanomedicine,” Nanowerk Spotlight, Available: www.nanowerk.com/spotlight/spotid=1891.php

  • D. Sarko, and R. B. Georges, “Kidney-specific drug delivery: Review of opportunities, achievements, and challenges,” Journal of Analytical and Pharmaceutical Research, vol. 2, no. 5, 2016.

  • Y. Gilad, M. Firer, and G. Gellerman, “Recent innovations in peptide based targeted drug delivery to cancer cells,” Biomedicines, vol. 4, no. 11, pp. 1-24, 2016.

  • L. M. Kranz, M. Diken, H. Haas, S. Kreiter, …….., and U. Shahin, “Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy,” Nature, no. 534, pp. 396-401, June 2016. Available: www.nature.com/nature/journal/v534/n7607/full/nature18300.html

  • D. Liu, F. Yang, F. Xiong, and N. Gu, “The smart drug delivery system and its clinical potential,” Theranostics, vol. 6, no. 9, pp. 1306-1323, 2016.

  • J. Lovric, H. S. Bazzi, Y. Cuie, G. R. Fortin, F. M. Winnik, and D. Maysinger, “Differences in subcellular distribution and toxicity of green and red emitting CdTe quantum dots,” Journal Molecular Medicine, vol. 83, no. 5, pp. 377-385, May 2005.

  • N. Martinho, C. Damge, and C. P. Reis, “Recent advances in drug delivery systems,” Journal of Biomaterials and Nanobiotechnology, vol. 2, no. 5A, pp. 510-526, December 2011.

  • N. Mishra, P. Pant, A. Porwal, J. Jaiswal, M. A. Samad, and S. Tiwari, “Targeted drug delivery: A review,” American Journal of Pharmtech Research, vol. 6, no.1, February 2016.

  • A. P. Nikalje, “Nanotechnology and its applications in medicine,” Medicinal Chemistry, vol. 5, no. 2, pp. 081-089, March 2015.

  • G. Oberdorser, E. Oberdorser, and J. Oberdorser, “Concepts of nanoparticles dose metric and response metric,” Environmental Health Perspectives, vol. 115, no. 6, p. A290, June 2007.

  • W. M. Pardridge, “Blood-brain barrier delivery,” Drug Discovery Today, vol. 12, no. 1-2, pp. 54-61, January 2007.

  • X. H. Peng, X. Qian, H. Mao, A. Y. Wang, Z. G. Chen, S. Nie, and D. M. Shin, “Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy,” International Journal of Nanomedicine, vol. 3, no. 3, pp. 311-321, 2008.

  • A. Radomski, P. Jurasz, D. A. Escolano, M. Drews, M. Morandi, T. Malinski, and M. W. Radomski, “Nanoparticle-induced platelet aggregation and vascular thrombosis,” British Journal of Pharmacology, vol. 146, no. 6, pp. 882-893, November 2005.

  • S. Ranghar, P. Sirohi, P. Verma, and V. Agarwal, “Nanoparticle-based drug delivery systems: Promising approaches against infections,” Brazilian Archives of Biology and Technology, vol. 57, no. 2, March-April 2014.

  • A. K. Rai, R. Tiwari, P. Maurya, and P. Yadav, “Dendrimers: A potential carrier for targeted drug delivery system,” Pharmaceutical and Biological Evaluations, vol. 3, no. 3, pp. 275-287, June 2016.

  • K. Rani, and S. Paliwal, “A review on targeted drug delivery: Its entire focus on advanced therapeutics and diagnostics,” Scholars Journal of Applied Medical Sciences, vol. 2, no. 1C, pp. 328-331, January 2014.

  • D. Resnik, “Clinical trials of nanomedicine; Ethical and safety issues,” Research Practitioner, 2016. Available: www.accessmylibrary.com/coms2/summary_0286-29032454_ITM.

  • G. R. Rudramurthy, M. K. Swamy, U. R. Sinniah, and A. Ghasemzadeh, “Nanoparticles: Alternatives against drug-resistant pathogenic microbes,” Molecules, vol.21, no. 7, June 2016.

  • C. M. Sayes, F. Liang, J. L. Hudson, J. Mendez, ……., and V. L. Colvin, “Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro,” Toxicology Letters, vol. 161, no. 2, pp. 135-142, February 2016.

  • G. Sharma, A. R. Sharma, J. S. Nam, G. P. C. Doss, S.S. Lee, and C. Chakraborty, “Nanoparticle based insulin delivery system: The next generation efficient therapy for Type 1 diabetes,” Journal of Nanobiotechnology, vol. 13, no. 74, October 2015.

  • A. A. Shvedova, V. Castranova, E. R. Kisin, D. S. Berry, A. R. Murray, V. Z. Gandelsman, A. Maynard, and P. Baron, “Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells,” Journal of Toxicology and Environmental Health A, vol. 66, no. 20, pp. 1909-1926, October 2003.

  • A. Srivastava, T. Yadav, S. Sharma, A. Nayak, A. Kumari, and N. Mishra, “Polymers in drug delivery,” Journal of Biosciences and Medicines, vol. 4, no. 1, pp. 69-84, January 2016.

  • S. Tinkle, S. E. McNeil, S. Muhlebach, R. Bawa, G. Borchard, Y. C. Barenholz, L. Tamarkin, and N. Desai, “Nanomedicines: Addressing the scientific and regulatory gap,” Annals of the New York Academy of Sciences, vol. 1313, pp. 35-56, April 2014.

  • G. Tiwari, R. Tiwari, B. Sriwastawa, L. Bhati, S.Pandey, P. Pandey, and S. K. Bannerjee, “Drug delivery systems: An updated review,” International Journal of Pharmaceutical Investigations, vol. 2, no. 1, pp. 2-11, January-March 2012.

  • S. Vijayakumar, and S. Paulsi, “Gold nanoparticles in early detection and treatment of cancer: Biodistribution and toxicities,” International Journal of Pharmaceutical Sciences Review and Research, vol. 20, no. 2, pp. 80-88, May-June 2013.

  • J. J. Wang, Z. W. Zeng, R. Z. Xiao, T. Xie, G. L. Zhou, X. R. Zhan, and S. L. Wang, “Recent advances of chitosan nanoparticles as drug carriers,” International Journal Nanomedicine, vol. 6, pp. 765-774, 2011.

  • M. A. Woldu, and J. L. Lenjisa, “Nanoparticles and the new era in diabetes management,” International Journal of Basic and Clinical Pharmacology, vol. 3, no. 2, pp.277-284, March-April 2014.

  • R. Xu, G. Zhang, J. Mai, X. Deng, ……….., and H. Shen, “An injectable nanoparticle generator enhances delivery of cancer therapeutics,” Nature Biotechnology, vol. 34, no. 4, pp. 414-418, 2016.

  • Z. Yang, W. Tang, X. Luo, X. Zhang, C. Zhang, H. Li, D.Gao, H. Luo, Q. Jiang, and J. Liu, “Dual-ligand modified polymer-lipid hybrid nanoparticles for docetaxel targeting delivery to Her2/neu overexpressed human breast cancer cells,” Journal of Biomedical Nanotechnology, vol. 11, no. 8, pp.1401-1417, August 2015.


Abstract Views: 297

PDF Views: 5




  • Review:Chitosan Nanoparticles for Effective and Safe Drug Delivery:Potential Big Deal in Intellectual Property Business

Abstract Views: 297  |  PDF Views: 5

Authors

J. G. Shantha Siri
Nano Technology Research Laboratory, Department of Electronics, Wayamba University of Sri Lanka, Kuliyapitiya, Sri Lanka
C. A. N. Fernando
Nano Technology Research Laboratory, Department of Electronics, Wayamba University of Sri Lanka, Kuliyapitiya, Sri Lanka
N. De Silva
Nano Technology Research Laboratory, Department of Electronics, Wayamba University of Sri Lanka, Kuliyapitiya, Sri Lanka

Abstract


According to the world drug report 2016 of United Nations Office on Drug and Crime, over 29 million people who use drugs are estimated to suffer from drug use disorders. It is estimated that 1 in 20 adults, or a quarter of a billion people between the ages of 15 and 64 years, used at least one drug in 2014. The estimated 207, 400 drug-related deaths in 2014 is corresponding to 43.5 deaths per million people aged 15-64. The number of drug-related deaths worldwide has also remained stable, although unacceptable and preventable.

The use of conventional antimicrobial agents against infections is always associated with problems such as the development of multiple drug resistance and adverse side effects. In addition, the inefficient traditional drug delivery system results in inadequate therapeutic index, low bio-availability of drugs, inefficient delivery of the drugs, causing systemic side effects, problems of poor uptake and destruction of drugs (when orally administered).

One of the most dynamic research areas in the field of nanotechnology is nano-medicine and target drug delivery is one of the highly specific medical interventions for prevention, diagnosis and treatment of diseases. Problems associated with conventional drug administration methods may potentially be overcome by these novel drug delivery methods. Researchers have been able to develop targeted and sustained drug delivery platforms harnessing unique physico-chemical properties of nano-particles. Advances in research on bio-compatible polymeric nano-particles have enabled more efficient and safer delivery of drugs with improved pharmacokinetics and pharmacodynamics with reduced side effects. Total market size of nanotechnology in drug delivery in 2021 is forecasted to be US$136 billion. Trends also suggest that the number of nanotechnology products and workers worldwide will double every 3 years, achieving a US$3 trillion market with six million workers by 2020. Chitosan nanoparticles seem to be the most promising comnanoparticle that can be used for developing multipurpose drug carrier platforms due to its biocompatibility, mucoadhesivity, non-toxicity and biodegradability.

Despite of potential benefits of nanoparticles in target drug delivery, there are certain engineered nanomaterials which can lead to unforeseen environmental, health and safety risks. Therefore, adequate attention is needed from the beginning in order to ensure sustainable nanotechnology. This review article is focused on frontier research, toxicity evidence and patent filing trends in applications of chitosan nanoparticles with an emphasis on target drug delivery.


Keywords


Biocompatible, Chitosan Nanoparticles, Hazards and Risks, Nanomedicine, Nanotechnology, Patents, Pharmacodynamics, Pharmacokinetics, Targeted Drug Delivery.

References